Coloplast reported mixed Q3 21 numbers, missing top-line estimates but beating on the bottom line. Sales were up 11% on an organic basis, driven by Urology (+82%) and ‘wound & skin care’ (+17%). Adjusted EBIT was up 16%, with the associated margin at 33%.
FY21 top-line growth is now expected to be at the lower end of 7-8%, while the adjusted EBIT margin is expected to be at the higher end of 32-33%.
We do not expect any significant changes to our estimates.
Companies: Coloplast A/S Class B (COLO.B:CSE)Coloplast (COLO-B:CPH)
Coloplast reported mixed Q2/H1 2021 numbers. Sales were up 2% on an organic basis, driven by ostomy (+4%) and urology (+3%). Adjusted EBIT was up 2% with the associated margin at 33% (+100bp).
FY21 top-line growth outlook was maintained (7-8% organic, 4-5% in DKK), while the adjusted EBIT margin is now expected at 32-33% (vs 31-32% earlier).
We do not expect any significant changes to our estimates, as we believe the soft Q2 showing should be offset by stronger H2 growth.
Coloplast announced good Q1 21 numbers, even though it missed our estimates. Revenue was up 5% on an organic basis, driven by chronic care (+5%) and urology (+5%), which offset soft wound & skin (+1%). Adjusted EBIT came in at DKK1.5bn with the margin at 32% (+100bp).
FY21 outlook remains unchanged with 7-8% top-line growth and a 31-32% EBIT margin.
Factoring in the marginal miss vs our estimates, we will trim our estimates accordingly, with little impact on the target price.
Companies: Coloplast A/S Class B
Coloplast reported mixed Q4 20 numbers – missing revenue estimates and beating on profits. Sales were up 2% to DKK4.6bn – driven by ostomy and continence – while the EBIT margin was unchanged at 32%. The board proposed a final dividend of DKK13/share. For FY21, management expects top-line growth of 7-8% and an EBIT margin of 31-32%, largely in line with estimates. Following the largely expected performance, we do not expect any significant changes in our estimates/recommendation.
Coloplast reported soft Q3 20 numbers as sales declined 2% on an organic basis, while the EBIT margin came in at 31%. The softness was driven by a 40%/6% decline in Urology/Wound & Skin, which more than offset the 4% growth in chronic care. The company lowered FY20 growth expectations (4% vs 4-6% earlier) while increasing the EBIT margin guidance to 31% (vs 30-31% earlier). We will be lowering our estimates to factor in the soft performance.
Coloplast reported strong Q2 20 numbers. Sales (driven by chronic care) rose 9% on an organic basis, with the EBIT margin at 32% (+1pp due to operating leverage and cost-cutting). The company announced a dividend of DKK5/share and re-iterated FY20 expectations (4-6% topline growth, 30-31% EBIT margin). Capex will be increased to DKK950m (vs DKK 850m earlier), in order to boost production. In anticipation of unwinding stockpiling effects, we do not expect any significant changes to our estimates.
Coloplast announced good Q1 20 numbers – trumping estimates on both the topline and bottomline. Sales were up 8% on an organic basis – driven by wound and skin care (+10%), ostomy (+9%), urology (+9%) – and the EBIT margin came in at 31%. Management re-iterated its FY 2020 guidance: topline growth of 7-8%, EBIT margin at ~31%, capex around DKK850m and an effective tax rate of nearly 23%. Following the Q1 numbers, we will be making minor upward revisions in our estimates.
Coloplast reported mixed Q4 19 numbers – in line revenue and a miss on the bottom-line. Sales were up 8% on an organic basis, led by strong growth in Urology (+11%), while the EBIT margin came in at 32%. For FY 20, management expects 7-8% organic top-line growth and an EBIT margin of ~31% at CER with a neutral FX impact. Following the largely in line performance, we do not expect any major changes in our estimates.
Coloplast reported Q3 19 numbers in line with consensus as well as our estimates. Sales were up 8% on an organic basis, driven by broad-based growth across segments, while the EBIT margin came in at 31%. Management re-iterated its FY 2019 expectations: organic growth of ~8% (reported growth of ~9%) and an EBIT margin of 30-31% at CER (~31% reported). Following the largely in line performance, we do not expect any major change in our estimates.
Coloplast reported Q2 19 numbers in line with consensus but marginally above our estimates. Sales were up 8% on a CER basis – driven by urology, continence care and wound care – while the EBIT margin came in at 30.5%. Management re-iterated its FY 2019 growth expectation of ~8% at CER but upgraded reported growth expectations (~9% vs 8-9% earlier). The EBIT margin expectations remain unchanged (30-31% CER; ~31% reported). Following the largely in line numbers, we do not expect any major change i
Coloplast reported mixed Q1 19 numbers – meeting top-line estimates and marginally missing on profitability. Sales grew by 8% – with all segments reporting strong growth. The EBIT margin contracted marginally and came in at 30.4%. FY2019 guidance was maintained. Following the largely in line performance, we do not expect any major change to our estimates or rating.
Coloplast missed the street’s estimates across the board in Q4 18, but largely met our rather conservative estimates. Sales grew by 8% – a strong urology and ostomy performance was partly offset by a mixed performance in wound and skin care. The EBIT margin – helped by margin expansion in urology and wound care – came in above expectations at 31.3%. In spite of the decent Q4, a possibility of further reform headwinds in 2019 keep our estimates and rating largely unchanged.
Coloplast’s Q3 18 top-line came in better than our expectations but missed the street’s expectations by a whisker. The bottom-line, on the other hand, lagged ours as well as the street’s estimates. Wound care and urology reported a sequential acceleration while chronic care (continence and ostomy), even though delivered another quarter of market-beating growth, wasn’t better sequentially. Factoring in the Q3 numbers, we will make minor tweaks to our estimates, but we do not foresee any significa
Coloplast’s Q2 2018 results came in above our estimates on the top line while under-performing our bottom-line estimates. Segment-wise, Ostomy and Continence care maintained momentum, Wound Care bounced back while Skin Care disappointed. The company remained confident of the current investment and cost rationalisation efforts paying off from 2019-20. We have nudged up our long-term margin estimates and forecasts, but maintain a reduce recommendation, and believe that the recent rally has been t
Coloplast’s Q1 18 results came in slightly below expectations, at both the top-line as well as the bottom-line. The strength in the Ostomy and Continence care segments was offset by weakness in wound care. We have tweaked our numbers based on the Q1 results and the Lilial acquisition, but maintain our recommendation on the stock.
Research Tree provides access to ongoing research coverage, media content and regulatory news on Coloplast A/S Class B.
We currently have 1 research reports from 1
Full-year results were in line with the trading update of 21 July, with revenues of £31m (-2%), reflecting the impact of COVID-19 on out-patient procedure rates, resulting in 14% and 24% declines in adjusted EBITDA and pre-tax profit, respectively. Lower than expected procedure growth rates and the decision to discontinue non-core (non-chlorine dioxide products) reduces forecast revenues by c.£3m to £33m in FY 2022. However, higher gross profit and tight control of costs (+6%) results in an unch
Companies: Tristel Plc
No Joiners Today.
No Leavers Today.
What’s cooking in the IPO kitchen?
Devolver Digital to join AIM, an award-winning digital video games publisher and developer in the indie games space. Recently awarded indie 'Publisher of the Year 2021' by GamesIndustry.biz. Offer TBA. Due early Nov.
Life Science REIT to join AIM raising up to £100m. This will be the first London listed real estate investment trust (REIT) focused on UK life science properties providing investors with exposure
Companies: SYS1 ARE SO4 SNG TMG TMT OHG IDE KIBO MRL
Recruitment resumed the Phase 2a trial of the lead programme hRPC in retinitis pigmentosa (RP) with the treatment of the first UK-patient in Oxford. The protocol gives greater infection control after the safety issue (a possible infection) in June. Five patients were treated up to mid-October and the remaining four could be treated by December 2021. By late March 2022, ReNeuron expects to give an interim update. The full data set should be available around mid-2022. This will enable regulatory d
Companies: ReNeuron Group plc
Companies: WAND SDX SEMP BMK LVCG MOS ACC
IXICO has announced that one of its clients has put an indefinite halt on a clinical trial for which the company was providing its artificial intelligence medical image analysis. The halt is the result of unexpected preclinical data. IXICO had expected the contract to deliver £0.8m of revenues in FY22E and it represented £3.3m of the £18.8m order book as of the close September 2021. While this news is disappointing, clearly the trial halt has no reflection on the capability of IXICO's technology
Companies: IXICO Plc
No Joiners Today
No Leavers Today
What’s cooking in the IPO kitchen?
Arrow Exploration Corp. (AIM: AXL ; TSXV: AXL) , the oil and gas exploration and production company, has conditionally raised approximately £8.8m and is due to complete its dual listing on AIM on 25 Oct. Market cap c£13.1m.
Devolver Digital to join AIM, an award-winning digital video games publisher and developer in the indie games space. Recently awarded indie 'Publisher of the Year 2021' by GamesIndustry.biz.
Companies: ZYT CIC DMTR GILD LMS MMAG PYC SMRT SBI
H1 EBITDA declined by 45% YoY, albeit this was slightly better than we had anticipated after the pre-close update in August. The beat was cost related (efficiencies/savings). There was a significant gross margin drag though and, while transitory in nature and diminishing in H2, this means further savings need to be realised to hit full year forecasts. This is our view and we retain a good level of confidence in next year’s forecasts. Having de-rated, valuation looks very undemanding now on just
Companies: Venture Life Group Plc
IXICO has provided an upgraded trading statement for FY21E following its previous update in August 2021. Revenues are now expected to be £9.2m (vs £8.7m previously), broadly in line with FY20A, which we see as a strong result given the pandemic and Huntington's Disease (HD) trials de-scope. EBITDA is expected to be materially ahead of FY20A's £1.3m, supported by strong Q4/21 trading, cost control and positive one-offs. The company has ended FY21 with a strong order book (£18.8m) and cash positio
CareTech is a specialist social care and educational services provider. This morning, the group has announced an update for the year to 30 September pointing to the fact that results will be in line with market expectations. The net debt position of £259m illustrates a further reduction since the end of H1 (31 March £263.1m) and implying a reduction to 2.7x adjusted EBITDA. During the year, seven new developments have opened, with a further eight properties purchased in H2. The group's freehold
Companies: CareTech Holdings PLC
SkinBioTherapeutics has announced it will launch its lead commercial product, AxisBiotix-Ps on World Psoriasis Day, 29 October 2021. To support the launch, the company has begun to receive, and store finished product in the Netherlands (close to its manufacturing partner) ahead of initial launches in the UK and US. Clearly the launch of its first product is a significant step for SkinBioTherapeutics, marking the transition from development company to commercial operation. We are encouraged by th
Companies: SkinBioTherapeutics Plc
Synairgen reported interim results to 30 June in which the adjusted net loss was £32.8m with period-end cash of £46.2m. Substantial pre-commercial progress and manufacturing activities have made in the half, although slower country approvals for trial sites will result in Phase III data readout slipping into Q1 2022. With increasing evidence of the need for a broad-spectrum antiviral delivered to the lungs and recognition that vaccines don’t provide complete protection against hospitalisations d
Companies: Synairgen plc
*A corporate client of Hybridan LLP
No joiners today.
Conduity Capital has left AIM.
What’s cooking in the IPO kitchen?
Softline the global solutions and services provider in digital transformation and cybersecurity, with its headquarters in London, is considering proceeding with a potential initial public offering of global depositary receipts representing its ordinary shares. The Company is considering applying for admission of the GDRs to the standard listing segm
Companies: SEN SEMP DNORD DNORD FAB MAST SAR CZA MRL
No Joiners Today.
Cambria Autos has left the AIM following a takeover.
What’s cooking in the IPO kitchen?
Light Science Tech Holdings, the controlled environment agriculture technology and contract electronics manufacturing Group to join AIM. Raising £5m. Expected mkt cap £17.4m. Due 15 Oct.
Harmony Energy Income Trust to join the Specialist Fund Segment of the Main Market raising up to £230m. The Company's investment objective is to provide investors with an attractive and susta
Companies: VRS ORPH SNG MRL EBQ AVG
The positive market research results for Eroxon®, released this morning, provides further support for the company’s ongoing partnering efforts. We continue to believe that MED2002 is a differentiated product with significant potential in both prescription and OTC markets, and look forward to further PK data followed by Phase III start in H1 2018.
Companies: Futura Medical plc
Hikma’s H1 20 top-line acceleration was driven by COVID-19-related demand in Injectables and Generics and the economic recovery in Algeria propelled growth in the Branded segment. Combined with a favourable product-mix, the operating margin was up 1.5ppt. In the near term, new launches across segments should provide some respite against the ongoing pricing pressure. Given the company’s thin R&D pipeline and a robust balance sheet, M&A (probably in the biosimilars space) seems on the cards.
Companies: Hikma Pharmaceuticals Plc